NBDF/LinkedIn
Sep 10, 2025, 20:45
FDA Approves VONVENDI for Adults With All Types of von Willebrand Disease
National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:
”Big news for the bleeding disorders community:
The FDA has expanded approval of VONVENDI® to include prophylactic use for adults with all types of von Willebrand disease (VWD).
This marks an important step forward in reducing bleeding episodes and improving quality of life.”
Read more here.
Stay updated on the emerging in the field of bleeding disorders with Hemostasis Today.
-
Jul 9, 2026, 13:16Olivier Mathieu: Innovating the Future of Hemostasis at ISTH 2026
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders
-
Jul 9, 2026, 12:16Fernanda Betti Solano: Could Iron Deficiency Be Affecting Your Sleep?
-
Jul 9, 2026, 12:08Andreas Calatzis: What is the Rationale for Collagen-Induced Platelet Aggregation Testing?
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction